Updated Apr 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
|
|
- Alban Joseph
- 5 years ago
- Views:
Transcription
1 Local Esophageal Cancer Summary Updated Apr 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Reviewed by Dr. Yoo-Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer Centre, University of Toronto), Dr. Vincent Tam (Medical Oncologist, Tom Baker Cancer Centre, University of Calgary) DISCLAIMER: The following are study notes compiled by the above PGY-5 medical oncology residents and reviewed by a staff medical oncologist. They reflect what we feel is relevant knowledge for graduating medical oncology residents preparing for their final examination. The information has not been surveyed or ratified by the Royal College. Epidemiology Incidence: adenocarcinoma is increasing dramatically (?due to obesity), SCC decreasing over time. SCC comprises 90% of all esophageal cancers. - Incidence of superficial esophageal cancer is increasing, particularly in Asian countries where screening for upper digestive tract cancers is common - Similar trend in United States, attributed in part to routine endoscopic surveillance for malignancy and high-grade dysplasia in patients with Barrett's esophagus Risk factors Age Lifestyle - SCC: smoking, alcohol, betel nut chewing, N-nitroso containing foods - AdenoCA: obesity, smoking, N-nitroso foods Hereditary: Tylosis (hyperkaratosis palms and soles of feet) AD 17q25 for SCC Other - SCC: Achalasia, caustic stricture,?hpv, prior H&N SCC - AdenoCA: HP infection, Barrett s (GERD), obesity, Zollinger Ellison, prior cholecystectomy,?drugs that relax esophageal sphincter (nitrates, BDZ) Staging CT chest/abdomen/pelvis Endoscopy/EUS: biopsy, location, T staging PET: essential for pre-operative assessment Differences between squamous and adenocarcinoma in staging - In SCC, stages can change depending on grade and location Ø E.g. Poor grade, upper/middle location upgraded from 1Aà1B, 1Bà2A etc. - In adenocarcinoma, only TNM stages affect final stage. Upper (cervical) cancer, T4 generally difficult to resect and typically treated with chemoradiation. Multidisciplinary approach important Treatment Regional Lymphatic Drainage Upper (Cervical) scalene, internal jugular, upper and lower cervical, periesophageal, and supraclavicular Middle upper periesophageal (above the azygos vein), subcarinal, lower (Intrathoracic) periesophageal (below the azygos vein) Lower (GEJ) Lower esophageal (below the azygos vein), diaphragmatic, pericardial, left gastric, celiac Superficial Esophageal Cancer (up to 1A)
2 - Usually treated with surgery alone (esophagetomy); endoscopic mucosal resection is also an option, but not the preferred treatment Localized Esophageal Cancer chemoradiation therapy + surgery if resectable RT Alone - modern techniques (eg. 3D conformal [3D-CRT], IMRT) associated with more favorable toxicity profiles than those with lower energy units in earlier years - however, role of RT alone has been supplanted by combined chemort in the majority of pts despite a higher rate of treatment related toxicity Trimodality Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer (CROSS) (Van Hagen NEJM 2012) Primary Endpoint Inclusion/Exclusion Weekly administration of carboplatin (doses titrated to achieve an area under the curve of 2 mg per milliliter per minute) and paclitaxel (50 mg per square meter of body-surface area) for 5 weeks and concurrent radiotherapy (41.4 Gy in 23 fractions, 5 days per week), followed by surgery vs Surgery alone OS 366 with esophageal or junctional cancer 75% had adenoca 23% SCC 2% large cell undifferentiated carcinoma Size (N) 366 Results pcr 29% in chemort/surgery group Complete resection with no tumor within 1mm of the resection margin (R0) in 92% vs 69%. mos 49.4 mo vs 24.0 mo HR 0.657, p=0.003 Most common major heme toxic effects in chemort-surgery: leukopenia, and neutropenia Most common non-heme: anorexia, fatigue Postop complication similar in both groups. In hospital mortality 4% in both Other Comments Preop chemort improved survival among pts w potentially curable esophageal or EGJ cancer. The regimen was associated w acceptable adverse event rates 91% received full treatment Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781 (Tepper JCO 2008) Esophagectomy with node dissection alone Vs Cisplatin/ 100mg/m2 fluorouracil 1000 mg/m2/d for 4 days on weeks 1 and 5 concurrent with RT (50.4Gy total: 1.8 Gy/fraction over 5.6 weeks) followed by esophagectomy with node dissection Inclusion/Exclusion Patients with nonmetastatic esophageal cancer Size (N) 475 Results mos 4.48 vs 1.79 years in favor of trimodality therapy (p=0.002) 5 year survival 39% vs 16% in favor of trimodality therapy The results from this trial reflect long term survival advantage with use of chemort followed by surgery in treatment of esophageal cancer, and support trimodality therapy as a standard of care for pts with this disease
3 Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901 (Mariette JCO 2014) Surgery alone Vs NCRT followed by surgery (45Gy in 25 fractions over 5 weeks with 2 courses of concomitant chemo compared to 5FU 800mg/m2 and cisplatin 75mg/m2 mfu 93.6 mo Primary Endpoint OS Inclusion/Exclusion Patients with localized cancers of the esophagus (ie stage I or II) Size (N) 195 Results R0 resection rate 93.8 vs 92.1% (p=0.749) 3 years OS 47.5 vs 53.0, HR 0.99, p=0.94 Postop mortality rate 11.1% vs 3.4% (p=0.049) Because interim analysis of the 1ry endpoint revealed an improbability of showing the superiority of either treatment arm(hr 1.09, p=0.66), the trial was stopped for anticipated futility Compare w surgery alone, NCRT w cisplatin plus FU does not improve R0 resection rate or survival but enhances postop mortality in pts w stage I or II EC (take this with a grain of salt, however). Trial stopped early after prespecified interim analysis due to treatment futility Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer (Van Hagen NEJM 2012) Neoadjuvant chemort before surgery Primary Endpoint Inclusion/Exclusion 17 trials from previous meta-analysis and 7 further studies updated analysis has 4188 pts Size (N) Results HR for all-cause mortality for neoadjuvant chemort was 0.78, p< HR for SCC only was 0.8 and for adenocarcinoma only was 0.75, p=0.02 HR for all-cause mortality for neoadjuvant chemo was 0.87, p=0.005 HR for SCC only was 0.92, p=0.18 and for adenoca only was 0.83, p=0.01) HR for overall indirect comparison of all-case mortality for neoadjuvant chemort vs neoadjuvant chemo was 0.88, p=0.07) This updated meta-analysis provides strong evidence for a survival benefit of neoadjuvant chemort or chemo over surgery alone in pts w esophageal carcinoma. A clear advantage of neoadjuvant chemort over neoadjuvant chemo has NOT been established Definitive chemoradiation therapy Chemoradiation With and Without Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of the Esophagus (Stahl JCO 2005) Primary Endpoint Inclusion/Exclusion Induction chemo followed by chemort (40Gy) followed by surgery (arm A) Vs the same induction chemo followed by chemort (at least 65Gy) without surgery (Arm B) OS Patients with locally advanced SCC of the esophagus
4 Size (N) 172 Results Local PFS better in surgery group (2 year PFS 40.7%, HR B vs A 2.1, p=0.003) OS equivalent between the 2 treatment groups(log-rank test for equivalence, p<0.05) Cox regression analysis revealed clinical tumor response to induction chemo to be the single independent prognostic factor for OS (HR 0.30, p<0.0001) Treatment related morality sig increased in surgery group than in chemort group(12.8 vs 3.5%, p=0.03). Adding surgery to chemort improves local tumor control but does not increase survival of pts w locally advanced esophageal SCC. Tumor response to induction chemo identifies a favorable prognostic group within these high risk pts, regardless of the treatment group. Combined Chemotherapy and Radiotherapy Compared with Radiotherapy Alone in Patients with Cancer of the Esophagus (Herskovic NEJM 1992) 4 courses of combined FU (1000mg/m2 daily for 4 days) and cisplatin (75mg/m2 on d1) +5000cGy of RT vs 6400cGy of RT alone Primary Endpoint OS Inclusion/Exclusion SCC or adenoca of the thoracic esophagus Size (N) 121 Results Pts getting combined treatment had fewer local (p<0.02) and for distant (p<0.01) recurrences mos 8.9 mo in RT treated pts vs 12.5 mo in chemort arm 5Y OS 26 vs 0% Severe and life threating side effects occurred in 44% and 20% of the pts who received combined therapy, as compared w 25% and 3% of those treated w RT alone Concurrent therapy w cisplatin and FU and RT is superior to RT alone in pts w localized carcinoma of the esophagus, as measured to by control of local tumors, distant mets, and survival, but at the cost of increased side effects. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. (Minsky JCO 2002) 4 monthly cycles of 5FU (1000mg/m2/24hours for 4 days) and cisplatin 75mgm2 bolus day 1) with concurrent 64.8 Gy vs. same chemo schedule but with concurrent 50.4Gy Inclusion/Exclusion Clinical stage T1-T4, N0/1, M0 SCC or adenocarcinoma selected for a nonsurgical approach Size (N) 218 Results NO DIFFERENCE IN: mos (13.0 vs 18.1 mo), 2 year survival (31 vs 40%) or local/regional failure and local/regional persistence of disease (56 vs 52%) between the high dose and standard dose arms Although 11 treatment related deaths occurred in the high dose arm compared w two in the standard dose arm, 7 of the 11 deaths occurred
5 in the patients who had received 50.4 Gy or less The higher RT dose did NOT increase survival or local/regional control Although there was a higher treatment related mortality rate in the pts assigned to the high dose RT arm, it did not seem to be related to the higher RT dose The standard RT dose for pts treated w concurrent 5FU and cisplatin chemo is 50.4Gy Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer (Conroy NEJM 2012) In Arm A (FOLFOX), patients received 6 bimonthly cycles: Oxaliplatin 85 mg/m2 d1, leucovorin 200 mg/m2 followed by 5-FU 400 mg/m2 bolus d1 then 1,600 mg/m2 46h continuous infusion The first 3 cycles were delivered concurrently with radiation therapy and the last 3 cycles were delivered adjuvantly. In Arm B (Cisplatin/5FU), patients received 4 cycles: Cisplatin 75 mg/m2 d1 followed by 5FU 1,000 mg/m2/d ci d1-4, The first 2 cycles were delivered concurrently with radiation therapy and the last 2 cycles were delivered adjuvantly Primary Endpoint PFS Inclusion/Exclusion Patients with technically unresectable esophageal cancer or those with surgical contraindications or who refused to undergo surgery Size (N) 267 Results The rate of 3 year PFS (18.2 vs.17.4%) was not statistically significantly different between the two arms. Additionally, the rate of complete response (41% vs. 41.3%), primary tumor failure (25.5 vs %), and median OS (20.2 vs months) was not significantly different. The FOLFOX arm had increased rates of peripheral neuropathy (18.3 vs. 0.8%, p<0.0001). The Cisplatin/5FU arm had increased rates of mucositis (32 vs. 26.7%, p=0.011), alopecia (9.4 vs. 1.5%, p=0.006), and renal toxicity (11.7 vs. 3.0%, p=0.036). Otherwise, grade 3/4 toxicities comparing FOLFOX vs. Cisplatin/5FU were not statistically significant: Hematologic: Neutropenia (29.0 vs. 28.9%), febrile neutropenia (5.3 vs. 7.0%), anemia 5.3 vs. 10.9%) and thrombocytopenia (6.9 vs. 7.8) GI-related: Esophagitis (6.9 vs. 12.5%), vomiting (3.8 vs. 2.4%) and diarrhea (1.5 vs. 0.7%) There was a trend toward more toxic deaths in the cisplatin/5fu arm (6.4 vs. 1.1%, p=0.06). Full treatment was delivered to 67.9% patients receiving FOLFOX and 72.2% receiving cisplatin/5fu (p=0.05). There was also no difference in treatment delay between the two arms. Neoadjuvant chemotherapy followed by surgery Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204. (Ando JCO 2003)
6 Surgery alone Vs surgery plus chemo, including 2 courses of cisplatin 80mg/m2 on d1) and FU 800mg/m2 x 5 days within 2 months after surgery Primary Endpoint Inclusion/Exclusion Size (N) 242 Results 5 year DFS 45% vs 55%, p=0.037 DFS Patients with localized SCC of thoracic esophagus, undergoing transthoracic esophagectomy w lymphadenectomy 5 year OS rate 52 vs 61%, p=0.13 (NONSIG) Grade 3 or 4 heme or nonheme toxicities were limited Postop adjuvant chemo w cisplatin and FU is better able to prevent relapse in pts w esophageal cancer than surgery alone Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer (MRC.OEO2) (Allum JCO 2009) Surgery alone (S) or to two cycles of combination cisplatin and fluorouracil before surgery (CS) Primary Endpoint OS Inclusion/Exclusion Patients undergoing radical surgery for esophageal cancer Size (N) 802 Results The survival benefit has been maintained with a hazard ratio (HR) of 0.84 (95% CI, 0.72 to 0.98; P =.03) which in absolute terms is a 5- year survival of 23.0% for CS compared with 17.1% for S. The treatment effect is consistent in both adenocarcinoma and squamous cell carcinoma. The first disease-free survival event was macroscopic residual disease from incomplete resection (R2) or no resection in 26.4% of the S group versus 14.3% of the CS P <.001. Three-year survival by type of resection was R0 42.4%, R1 was 18.0%, and R2 was 8.6%. Long-term follow-up confirms that preoperative chemotherapy improves survival in operable esophageal cancer and should be considered as a standard of care. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. (Stahl JCO 2009)
7 Induction chemo (15 weeks) followed by surgery (arm A) Vs Chemotherapy (12 weeks) followed by chemort (3 weeks) followed by surgery (Arm B) Treatment in arm A consisted of induction chemotherapy with 2.5 courses of cisplatin, fluorouracil, leucovorin (PLF). One course comprised a 6-week schedule of weekly fluorouracil (2 g/m2, 24-hour infusion) and leucovorin (500 mg/m2, 2-hour infusion) as well as biweekly cisplatin (50 mg/m2, 1-hour infusion). Treatment of arm B consisted of 2.0 courses of the same induction chemotherapy. This was followed by 3 weeks of combined chemoradiotherapy. Surgery was performed 3 to 4 weeks after the end of chemotherapy (arm A) or chemoradiotherapy (arm B). Primary Endpoint OS Inclusion/Exclusion Patients with locally advanced (ut3-4nxm0) adenocarcinoma of the lower esophagus or gastric cardia Size (N) 126 Results Arm B had a sig higher probability of showing pcr (15.6 vs 2%) or tumor free lymph nodes (64.4 vs 37.7%) at resection. Preop RT improved 3 year survival rate from 27.7% to 47.4% (p=0.07, HR 0.67) mos 21 vs 31m (significant) Postop mortality was nonsig increased in chemort group (10.2 vs 3.8%, p=0.26) Although the study was closed early and statistical sig was not achieved, results point to a survival advantage for preop chemort compared w preop chemo in adenocarcinomas of the EGJ Other Comments Initial results of CALGB (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer. (Goodman GI ASCO 2017) Randomized to one of 2 induction CT arms: Modified FOLFOX-6 (oxaliplatin, leucovorin, 5-FU), days 1, 15, 29 or Carboplatin/Paclitaxel (CP), days 1, 8, 22, 29. Repeat PET was performed days 36-42; change in max standardized uptake value (SUV) from baseline was assessed. PET non-responders ( 35% decrease in SUV PET-NR) crossed over to alternative CT regimen during CRT (50.4Gy/28 fractions). PET responders (>35% decrease in SUV PET-R) continued on same CT during CRT. Primary Endpoint pcr in PET-NR who crossed over to alternative chemotherapy Inclusion/Exclusion patients (pts) with resectable esophageal and gastroesophageal junction (GEJ) adenocarcinomas. Size (N) 257 Results FOLFOX vs CP PET-R 57 vs 50% pcr 38 vs 10% PET-NR 30 vs 38% pcr 16 vs 15% For PET-NR who crossed over to alternative CT during CRT, pcr was 15.6%; 95% CI (0.08, 0.26). Other Comments Efficacy criteria were met for an improvement in pcr rates among pts who were PET-NR after induction CT and received alternative CT during CRT for esophageal and GEJ adenoca. Pts receiving induction and concurrent CP had an unexpectedly low pcr.
8 Adjuvant therapy GEJ adenocarcinoma treated similarly to gastric adenocarcinoma (e.g. MAGIC, MacDonald protocol, ARTIST); no evidence for adjuvant therapy in SCC or upper/middle esophageal cancer. Utility of post induction therapy PET scans - Post induction therapy FDG-PET provides info about metabolic response in the primary tumor that may be clinically useful for selection of subsequent therapy. - In particular some retrospective data suggest that post-chemo FDG-PET scan may serve to identify those pts for whom surgery might be avoided - However, others have failed to find a correlation between the postchemort SUV on PET and pathologic response - Thus, these data need to be confirmed and validated in a prospective trial before PETdirected therapy for esophageal cancer can be considered a standard approach - The main use of PET may be to recognize which pts are not responding to induction chemo. Surveillance strategy No RCTs to guide postop surveillance strategy and no data that shows improvement or quality of life or longevity from earlier detection of asymptomatic recurrences. NCCN guidelines suggest: - Hx/Px q3-6 months for 1-3 years, then every 6 months for year 4 and 5, then annually - CBC and chemistry profile, as clinically indicated - Radiologic imaging and upper GI endoscopy, as clinically indicated - dilation for anastomotic stenosis - nutritional counseling
Medicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationManagement of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT
Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan Kettering Cancer Center Disclosure Consulting
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationNewly Diagnosed Cases Cancer Related Death NCI 2006 Data
Multi-Disciplinary Management of Esophageal Cancer: Surgical and Medical Steps Forward Alarming Thoracic Twin Towers 200000 150000 UCSF UCD Thoracic Oncology Conference November 21, 2009 100000 50000 0
More informationThe role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationANAL CANCER Updated May 2016 by Dr. Daniel Yokom (PGY-5 Medical Oncology Resident, University of Toronto)
ANAL CANCER Updated May 2016 by Dr. Daniel Yokom (PGY-5 Medical Oncology Resident, University of Toronto) Reviewed by Dr. Lee-Ying (Staff Medical Oncologist, University of Calgary), Dr. Kzyzanowska (Staff
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationUpdated Apr 2017 by Dr. Ko (Medical Oncologist, Abbotsford Cancer Centre)
Metastatic Esophagogastric Cancer Summary Updated Apr 2017 by Dr. Ko (Medical Oncologist, Abbotsford Cancer Centre) Reviewed by Dr. Yoo-Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer Centre, University
More informationCase Scenario year-old white male presented to personal physician with dyspepsia with reflux.
Case Scenario 1 57-year-old white male presented to personal physician with dyspepsia with reflux. 7/12 EGD: In the gastroesophageal junction we found an exophytic tumor. The tumor occupies approximately
More informationResectable locally advanced oesophagogastric cancer
Resectable locally advanced oesophagogastric cancer Clinical Case Discussion Florian Lordick University Cancer Center Leipzig University Clinic Leipzig Leipzig, Germany esmo.org DISCLOSURES Honoraria for
More informationWhich Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy
Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Joseph Chao, M.D. Assistant Clinical Professor Department of Medical Oncology & Therapeutics
More informationRadiotherapy for Gastric Cancer. Nitin Ohri, M.D. Montefiore Medical Center Albert Einstein College of Medicine 12/15/2012
Radiotherapy for Gastric Cancer Nitin Ohri, M.D. Montefiore Medical Center Albert Einstein College of Medicine 12/15/2012 Disclosures I have no conflicts of interest to disclose. Outline Background Treatment
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationMünch et al. Radiation Oncology (2017) 12:182 DOI /s y
Münch et al. Radiation Oncology (2017) 12:182 DOI 10.1186/s13014-017-0904-y RESEARCH Open Access Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients
More informationTreatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer
Treatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer Nobukazu Fuwa 1, Akinori Takada 2 and Takahiro Kato 3 1;Departments of Radiology, Hyogo Ion Beam Medical
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationEsophageal Cancer. Wesley A. Papenfuss MD FACS Surgical Oncology Aurora Cancer Care. David Demos MD Thoracic Surgery Aurora Cancer Care
Esophageal Cancer Wesley A. Papenfuss MD FACS Surgical Oncology Aurora Cancer Care David Demos MD Thoracic Surgery Aurora Cancer Care No Disclosures Learning Objectives Review the classification scheme
More informationUpper Gastrointestinal. Friday, March 2, :00 p.m. 2:45 p.m.
Upper Gastrointestinal Friday, March 2, 2018 2:00 p.m. 2:45 p.m. Social Q&A Use your phone, tablet, or laptop to Submit questions to speakers and moderators Answer interactive questions / audience response
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationTrimodality Therapy for Muscle Invasive Bladder Cancer
Trimodality Therapy for Muscle Invasive Bladder Cancer Brita Danielson, MD, FRCPC Radiation Oncologist, Cross Cancer Institute Assistant Professor, Department of Oncology University of Alberta Edmonton,
More informationHPV VACCINE AND AIN Palefsky NEJM 2011 n=602 MSM 16-26y qhpv = vaccine against HPV 6, 11, 16 and 18 vs placebo They analyzed ITT and per protocol.
ANAL CANCER Updated Mar 2017 by Doreen Ezeife, PGY-5 resident University of Calgary Reviewed by Dr. Lee-Ying (Staff Medical Oncologist, University of Calgary), Dr. Kzyzanowska (Staff Medical Oncologist,
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationThe PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer
The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer Robert I. Haddad, Guilherme Rabinowits, Roy B. Tishler,
More informationCarcinoma del retto: Highlights
Carcinoma del retto: Highlights Stefano Cordio Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania Roma 17 Febbraio 2018 Disclosures Advisory Committee, research funding and speakers bureau
More informationPerioperative chemotherapy: individualized therapy or same treatment for all? Prof. Dr. med. Salah-Eddin Al-Batran
Perioperative chemotherapy: individualized therapy or same treatment for all? Prof. Dr. med. Salah-Eddin Al-Batran Institute of Clinical Cancer Research Krankenhaus Nordwest UCT - University Cancer Center
More informationGynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.
Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD Conflict of Interests None Cervical cancer is the fourth most common malignancy in women worldwide 530,000 new cases per year
More informationA) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary), April 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Centre, BC Cancer
More informationOverview. What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013
What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013 Overview Staging and Workup Resectable Disease Surgery Adjuvant therapy Locally
More informationCase Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.
Case Scenario 1 July 10, 2010 A 67-year-old male with squamous cell carcinoma of the mid thoracic esophagus presents for surgical resection. The patient has completed preoperative chemoradiation. This
More informationMini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background
Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016 Background Mostly adenocarcinoma (scc possible, but treated like anal cancer) 39, 220 cases annually Primary treatment: surgery
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationOriginal Article. Division of Gastrointestinal and General Surgery, Department of Surgery, 2 Department of Radiation Medicine, 3
Diseases of the Esophagus (2017) 30, 1 7 DOI: 10.1093/dote/dox015 Original Article Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationEmerging Role of Immunotherapy in Head and Neck Cancer
Emerging Role of Immunotherapy in Head and Neck Cancer Jared Weiss, MD Associate Professor of Medicine and Section Chief of Thoracic and Head/Neck Oncology UNC Lineberger Comprehensive Cancer Center Copyright
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationGetting to the Bottom of Treatment: An Update in the Management of Esophagogastric Cancers
Getting to the Bottom of Treatment: An Update in the Management of Esophagogastric Cancers Disclosures None Cindy L. O Bryant, PharmD, BCOP, FCCP, FHOPA Professor, University of Colorado Skaggs School
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationHPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV
More informationSingle centre outcomes from definitive chemo-radiotherapy and single modality radiotherapy for locally advanced oesophageal cancer
Original Article Single centre outcomes from definitive chemo-radiotherapy and single modality radiotherapy for locally advanced oesophageal cancer Ben Alexander Fulton 1, Joanna Gray 2, Alexander McDonald
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationManagement of Esophageal Cancer: Evidence Based Review of Current Guidelines. Madhuri Rao, MD PGY-5 SUNY Downstate Medical Center
Management of Esophageal Cancer: Evidence Based Review of Current Guidelines Madhuri Rao, MD PGY-5 SUNY Downstate Medical Center Case Presentation 68 y/o male PMH: NIDDM, HTN, hyperlipidemia, CAD s/p stents,
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationUpper Gastrointestinal Cancers in the Elderly. Choo Su Pin Senior Consultant Medical Oncology National Cancer Centre Singapore
Upper Gastrointestinal Cancers in the Elderly Choo Su Pin Senior Consultant Medical Oncology National Cancer Centre Singapore Gastric Cancer --High Global Burden Global Cancer Deaths % of all cancer (2008)
More informationDetermining Resectability and Appropriate Surgery for Esophageal Cancer
Determining Resectability and Appropriate Surgery for Esophageal Cancer Peter Baik, DO, FACOS Thoracic Surgery Cancer Treatment Centers of America 1 Esophageal and Esophagogastric Junction Cancers Siewert
More informationMinimally Invasive Esophagectomy- Valuable. Jayer Chung, MD University of Colorado Health Sciences Center December 11, 2006
Minimally Invasive Esophagectomy- Valuable Jayer Chung, MD University of Colorado Health Sciences Center December 11, 2006 Overview Esophageal carcinoma What is minimally invasive esophagectomy (MIE)?
More informationNeoadjuvant chemoradiotherapy for esophageal/ gastroesophageal carcinoma
Original Article Neoadjuvant chemoradiotherapy for esophageal/ gastroesophageal carcinoma Timothy A. Platz 1, Steven J. Nurkin 1, Mei Ka Fong 2, Adrienne Groman 3, Leayn Flaherty 4, Usha Malhotra 5, Charles
More informationUPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER
UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review
More informationNEOADJUVANT THERAPY IN CARCINOMA STOMACH. Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Superspeciality Hospital, Howrah
NEOADJUVANT THERAPY IN CARCINOMA STOMACH Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Superspeciality Hospital, Howrah NEOADJUVANT THERAPY?! Few believers Limited evidence Many surgeons
More informationResearch and Reviews Journal of Medical and Clinical Oncology
Comparison and Prognostic Analysis of Elective Nodal Irradiation Using Definitive Radiotherapy versus Chemoradiotherapy for Treatment of Esophageal Cancer Keita M 1,2, Zhang Xueyuan 1, Deng Wenzhao 1,
More informationClinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer
DOI 10.1007/s10147-014-0736-9 ORIGINAL ARTICLE Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer Kazuki Ishikawa Kiyoshi Nakamatsu
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationPerioperative versus adjuvant management of gastric cancer, update 2013
Perioperative versus adjuvant management of gastric cancer, update 2013 Cornelis J.H. van de Velde, MD, PhD,FRCPS and FACS,Hon. Professor of Surgery President ECCO - the European Cancer Organization Past-President
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationEsophageal and GEJ Adenocarcinoma: Chemo + RT is the Preferred Treatment
Esophageal and GEJ Adenocarcinoma: Chemo + RT is the Preferred Treatment David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering Cancer Center Preop Therapy in Esophageal and
More informationAliu Sanni MD SUNY Downstate Medical Center August 16, 2012
Aliu Sanni MD SUNY Downstate Medical Center August 16, 2012 Case Presentation 60yr old AAF with PMH of CAD s/p PCI 1983, CVA, GERD, HTN presented with retrosternal chest pain on 06/12 Associated dysphagia
More informationControversies in management of squamous esophageal cancer
2015.06.12 12.47.48 Page 4(1) IS-1 Controversies in management of squamous esophageal cancer C S Pramesh Thoracic Surgery, Department of Surgical Oncology, Tata Memorial Centre, India In Asia, squamous
More informationQuiz Adenocarcinoma of the distal stomach has been increasing in the last 20 years. a. True b. False
Quiz 1 1. Which of the following are risk factors for esophagus cancer. a. Obesity b. Gastroesophageal reflux c. Smoking and Alcohol d. All of the above 2. Adenocarcinoma of the distal stomach has been
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationOptimal sequencing in treatment muscle invasive bladder cancer : oncologists. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
Optimal sequencing in treatment muscle invasive bladder cancer : oncologists Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Slide 2 Presented By Andrea Apolo at 2018 Genitourinary Cancers
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationImpact of esophageal cancer staging on overall survival and disease-free survival based on the 2010 AJCC classification by lymph nodes
Journal of Radiation Research, 2013, 54, 307 314 doi: 10.1093/jrr/rrs096 Advance Access Publication 2 November 2012 Impact of esophageal cancer staging on overall survival and disease-free survival based
More informationSurgical strategies in esophageal cancer
Gastro-Conference Berlin 2005 October 1-2, 2005 Surgical strategies in esophageal cancer J. Rüdiger Siewert Department of Surgery, Klinikum rechts der Isar Technische Universität München Esophageal Cancer
More information17. Oesophagus. Upper gastrointestinal cancer
110 17. Upper gastrointestinal cancer Oesophagus Radical treatment For patients with localised disease, the standard curative approach to treatment is either surgery + perioperative chemotherapy, surgery
More informationEsophageal cancer located at the cervical and upper thoracic
ORIGINAL ARTICLE Esophageal Cancer Located at the Neck and Upper Thorax Treated with Concurrent Chemoradiation: A Single- Institution Experience Shulian Wang, MD,* Zhongxing Liao, MD, Yuan Chen, MD, Joe
More informationPancreatic Cancer and Radiation Therapy
Pancreatic Cancer and Radiation Therapy Why? Is there a role for local therapy with radiation in a disease with such a high rate of distant metastases? When? Resectable Disease Is there a role for post-op
More informationPre- Versus Post-operative Radiotherapy
Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationARROCase: Locally Advanced Endometrial Cancer
ARROCase: Locally Advanced Endometrial Cancer Charles Vu, MD (PGY-3) Faculty Advisor: Peter Y. Chen, MD, FACR Beaumont Health (Royal Oak, MI) November 2016 Case 62yo female with a 3yr history of vaginal
More information肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
More informationNeo- and adjuvant treatment for gastric cancer: The role of chemotherapy
Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy Priv. Doz. Dr. Dr. med. T.O. Götze Institute of Clinical Cancer Research Director: Prof. Dr. S.-E. Al- Batran University Cancer
More informationAdjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD
Adjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD Efficacy Parameters in adjuvant monochemotherapy Randomized studies in resectable PDAC Regimen DFS HR (p) OS HR (p) 5-yr-OS
More informationSeptember 10, Dear Dr. Clark,
September 10, 2015 Peter E. Clark, MD Chair, NCCN Bladder Cancer Guidelines (Version 2.2015) Associate Professor of Urologic Surgery Vanderbilt Ingram Cancer Center Nashville, TN 37232 Dear Dr. Clark,
More informationWhere are we with radiotherapy for biliary tract cancers?
Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute
More informationLocally advanced head and neck cancer
Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary
More informationUpdate on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationOriginal article. Department of Radiation Medicine, 2 Division of Medical Oncology, Department of Internal Medicine, 3
Diseases of the Esophagus (2015), DOI: 10.1111/dote.12377 Original article Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen
More informationThe International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology
The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies
More informationPancreatic Adenocarcinoma
Pancreatic Adenocarcinoma AProf Lara Lipton 28 April 2018 Percentage alive 5 years after diagnosis for men and women Epidemiology 6% of cancer related deaths worldwide 4 th highest cause of cancer death
More informationintent treatment be in the elderly?
Gastric cancer: How strong can curative intent treatment be in the elderly? Caio Max S. Rocha Lima, M.D. Professor of Medicine University of Miami & Sylvester Cancer Center Gastric cancer: epidemiology
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationChapter 5 Stage III and IVa disease
Page 55 Chapter 5 Stage III and IVa disease Overview Concurrent chemoradiotherapy (CCRT) is recommended for stage III and IVa disease. Recommended regimen for the chemotherapy portion generally include
More informationEsophageal Cancer: A Multimodality Approach to Detection and Staging
Esophageal Cancer: A Multimodality Approach to Detection and Staging, MBA Topic: Esophageal Cancer Imaging: A multimodality approach Conference: Society of Thoracic Imaging Location: Date/Time: March 14,
More informationWorkshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI
XXI CONGRESSO NAZIONALE AIRO Genova, 19-22 novembre 2011 Workshop LA RADIOTERAPIA DEI TUMORI RARI I TIMOMI : INDICAZIONI PIERA NAVARRIA Unità Operativa di Radioterapia e Radiochirurgia Humanitas Cancer
More informationOptimization of treatment strategies and prognostication for patients with esophageal cancer Anderegg, M.C.J.
UvA-DARE (Digital Academic Repository) Optimization of treatment strategies and prognostication for patients with esophageal cancer Anderegg, M.C.J. Link to publication Citation for published version (APA):
More informationPILOT STUDY OF CONCURRENT CHEMO-RADIOTHERAPY FOR ADVANCED NASOPHARYNGEAL CARCINOMA (Forum for Nuclear Cooperation in Asia)
PILOT STUDY OF CONCURRENT CHEMO-RADIOTHERAPY FOR ADVANCED NASOPHARYNGEAL CARCINOMA (Forum for Nuclear Cooperation in Asia) Dr. Miriam Joy C. Calaguas Dept. of Radiation Oncology St. Luke s Medical Center
More informationHead and Neck Reirradiation: Perils and Practice
Head and Neck Reirradiation: Perils and Practice David J. Sher, MD, MPH Department of Radiation Oncology Dana-Farber Cancer Institute/ Brigham and Women s Hospital Conflicts of Interest No conflicts of
More informationNeoplasie del laringe Diagnosi e trattamento
Neoplasie del laringe Diagnosi e trattamento Venerdì 22 maggio 2015 Alessandria Trattamenti non chirurgici: Preservazione d organo, malattia localmente avanzata Marco C Merlano A.O. S.Croce e Carle, Ospedale
More informationOrgan-Preservation Strategies in head and neck cancer. Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari
Organ-Preservation Strategies in head and neck cancer Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari Larynx Hypopharynx The goal of treatment is to achieve larynx preservation
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationNeo- and adjuvant treatment for gastric cancer: The role of chemotherapy
Anna Dorothea Wagner, PD & MER Department of Oncology University of Lausanne Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy Structure 1. Background and overview 2. Adjuvant chemotherapy:
More information